Financial News
Merck's Keytruda reduced risk of disease recurrence or death in early lung cancer patients by 24%
March 17, 2022 at 14:19 PM EDT
Merck plans to submit the data on early stage lung cancer to the FDA as soon as possible.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
